Stock Alert: IM Cannabis (IMCC) Climbing 11.24% in Pre-Market Trading for August 5

Equities Staff  |

IM Cannabis Corp (NASDAQ:IMCC) has already gained $0.048 in early trading Friday.

After closing the previous trading session at $0.43, IM Cannabis has moved 11.24% higher ahead of market open.

The company has decreased 8.88% over the last 5 days.

Today could shape up to be an attractive day for IM Cannabis investors.

For technical charts, analysis, and more on IM Cannabis Corp visit the company profile.

Pre-market prices and movements as of 08:08:38 est.

About IM Cannabis Corp

IMC is an MCO in the medical cannabis sector headquartered in Israel and with operations In Israel and Germany. Over the past decade, the Company believes that the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market. The Company has also expanded its business to offer intellectual property-related services to the medical cannabis industry. In Europe, IMC operates through Adjupharm GmbH ("Adjupharm"), a German-based subsidiary and EU-GMP certified medical cannabis distributor. IMC's European presence is augmented by strategic alliances with various pan-European EU-GMP cultivators and distributors to capitalize on the increased demand for medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.

To get more information on IM Cannabis Corp and to follow the company's latest updates, you can visit the company's profile page here: IM Cannabis Corp's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation

Market Movers

Sponsored Financial Content